French national health insurance information system and the permanent beneficiaries sample.

In France, in the early 2000s, legislators ordered that the National Health Insurance regime develop an inter-regime information system (SNIIR-AM) aimed at better understanding and evaluating beneficiaries' health care consumption and associated expenditures. In 2009, it contained data from the general health insurance regime that covers 86% of the French population; approximately 53 million people. Data are only available for a period of two years plus the current year. In addition, a permanent sample of health insurance beneficiaries (EGB) was created from the SNIIR-AM database. This is a permanent, representative cross-sectional sample of the population covered by National Health Insurance which, since 2004, monitors beneficiaries' health care consumption over a period of 20 years. It contains anonymous sociodemographic and medical characteristics and records of health care reimbursements. It was created using a systematic sampling method (1/97) on the two-digit control key of beneficiaries' national identification number and includes both current year reimbursement recipients and non-recipients. In 2009, it grouped together almost 500,000 beneficiaries covered by the National Health Insurance Fund for Salaried Workers; 77% of the population residing in France excluding public service employees and students. The EGB is used to conduct longitudinal studies as it permits tracing back patients' care paths and use of care in both hospital and office-based care environments and to calculate individual expenditures. It also permits the study of certain relatively frequent diseases characterised by a 100% reimbursement rate for certain chronic diseases and the reimbursement of tracer drugs. Eventually, the SNIIR-AM will include beneficiaries covered by all the different Health Insurance regimes in France.

[1]  L. Roquefeuil,et al.  L'échantillon généraliste de bénéficiaires : représentativité, portée et limites , 2009 .

[2]  F. Carbonnel,et al.  Fine‐scale geographic variations of inflammatory bowel disease in France: Correlation with socioeconomic and house equipment variables , 2010, Inflammatory bowel diseases.

[3]  A. Weill,et al.  Primary Health Care Use and Reasons for Hospital Admissions in Dementia Patients in France: Database Study for 2007 , 2009, Dementia and Geriatric Cognitive Disorders.

[4]  J. Dartigues,et al.  BMC Geriatrics BioMed Central , 2009 .

[5]  J Raftery,et al.  Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. , 2005, Health technology assessment.

[6]  Bruce M Psaty,et al.  Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. , 2008, JAMA.

[7]  A. Weill,et al.  Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006. , 2009, Bulletin du cancer.

[8]  B. Salanave,et al.  Prevalence and treatment of diabetes in France: trends between 2000 and 2005. , 2008, Diabetes & metabolism.

[9]  V. Jooste,et al.  Cost of care of colorectal cancers according to health care patterns and stage at diagnosis in France , 2008, The European Journal of Health Economics.

[10]  P. Verger,et al.  Impact de l’estimation de la population affiliée à l’assurance-maladie sur le calcul de la prévalence pharmacologique du diabète à l’échelle régionale et territoriale , 2009 .

[11]  B. Bégaud,et al.  Pharmacoepidemiological research using French reimbursement databases: yes we can! , 2010, Pharmacoepidemiology and drug safety.

[12]  N. Danchin,et al.  Combined secondary prevention after hospitalization for myocardial infarction in France: analysis from a large administrative database. , 2009, Archives of cardiovascular diseases.

[13]  J. Avorn,et al.  A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.

[14]  P. Verger,et al.  [Impact of the estimation of the medically insured population on the pharmacological prevalence of diabetes at the regional and small area level]. , 2009, Revue d'epidemiologie et de sante publique.

[15]  A. Fagot-Campagna,et al.  Self-monitoring of blood glucose in people with type 1 and type 2 diabetes living in France: the Entred study 2001. , 2008, Diabetes & metabolism.

[16]  F A Allaert,et al.  FOIN: a nominative information occultation function. , 1997, Studies in health technology and informatics.

[17]  J. Dartigues,et al.  Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three‐City (3C) Study , 2009, Pharmacoepidemiology and drug safety.

[18]  J Raftery,et al.  Potential use of routine databases in health technology assessment. , 2005, Health technology assessment.

[19]  V. Rodwin The health care system under French national health insurance: lessons for health reform in the United States. , 2003, American journal of public health.

[20]  Gerald F Riley,et al.  Administrative and Claims Records as Sources of Health Care Cost Data , 2009, Medical care.

[21]  J. Benichou,et al.  Impact of Prescriber Nonresponse on Patient Representativeness , 2008, Epidemiology.

[22]  P. Böelle,et al.  Significant Reduction of Antibiotic Use in the Community after a Nationwide Campaign in France, 2002–2007 , 2009, PLoS medicine.

[23]  M. Goldberg [Administrative data bases: could they be useful for epidemiology?]. , 2006, Revue d'epidemiologie et de sante publique.